https://scholars.lib.ntu.edu.tw/handle/123456789/581997
標題: | IL28B genotype on HCV infection in Asia | 作者: | CHEN-HUA LIU JIA-HORNG KAO |
公開日期: | 2013 | 卷: | 12 | 期: | 3 | 起(迄)頁: | 149-156 | 來源出版物: | Current Hepatitis Reports | 摘要: | Hepatitis C virus (HCV) infection is the leading cause of cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC). Successful HCV eradication can reduce the liver-related mortality and morbidity. Previous studies show that Asian HCV-1 patients tend to have higher sustained virologic response (SVR) rates than Caucasian, Hispanic or African-American HCV-1 patients. Recent genome-wide association studies (GWAS) reveal interleukin-28B (IL28B) genotypes at locus rs12979860 or rs8099917 are strong predictors for SVR in HCV-1 patients treated with peginterferon-α (PEG-IFN-α) plus ribavirin (RBV), and the higher frequencies of favorable IL28B genotype in Asian patients than those in other ethnicity may explain the superior response in Asian HCV-1 patients. However, the predictive role of IL28B genotype is limited for HCV-2 patients and for HCV patients with response-guided therapy. IL28B genotype still predicts SVR in patients with triple therapy by telaprevir (TVR) or boceprevir (BOC). For newer direct-acting antivirals (DAAs), its predictive role remains to be confirmed. ? 2013 Springer Science+Business Media New York. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881256850&doi=10.1007%2fs11901-013-0176-4&partnerID=40&md5=0bd0a56c57cde8f4222b98bbb0240f10 https://scholars.lib.ntu.edu.tw/handle/123456789/581997 |
ISSN: | 1540-3416 | DOI: | 10.1007/s11901-013-0176-4 | SDG/關鍵字: | boceprevir; core protein; gamma interferon; interleukin 28B; peginterferon alpha; ribavirin; telaprevir; adaptive immunity; African American; Asia; Asian; Caucasian; drug cost; eradication therapy; ethnic difference; gene frequency; gene locus; gene mutation; genetic association; genetic variability; genome analysis; genotype; hepatitis C; Hepatitis C virus; Hepatitis C virus 1; Hepatitis C virus 2; Hispanic; histopathology; human; innate immunity; liver cell carcinoma; liver cirrhosis; medical decision making; pharmacogenetics; protein expression; review; treatment duration; treatment response; unspecified side effect; viral clearance; virus load |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。